Lab
Javon Bea Hospital
Javon Bea Hospital was paid $1.23M by Medicaid between Jan 2018 and Nov 2024, across 167 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 17% of everything it billed.
33Billing provider infoJAVON BEA HOSPITAL
ROCKFORD, IL 61114
ROCKFORD, IL 61114
33aNPI1629118609assigned 02/07/2007
33bProvider typeClinical Medical Laboratory
28Total paid$1.23M
24GClaims156,888
24DCodes billed167
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#69 of 235
Median peer was paid$123K
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MALAS, JOSEPH controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,751 | $580K | |
| 2019 | 64,995 | $407K | |
| 2020 | 28,690 | $207K | |
| 2021 | 915 | $5K | |
| 2022 | 995 | $10K | |
| 2023 | 653 | $9K | |
| 2024incomplete | 889 | $12K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 17% | 3,246 | 844 | $204K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 11% | 3,882 | 669 | $131K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.4% | 5,683 | 4,352 | $79K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.4% | 5,665 | 4,339 | $78K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.7% | 3,158 | 2,468 | $70K |
| 87507 | 5.5% | 300 | 288 | $67K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.2% | 1,272 | 1,198 | $64K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 4.4% | 5,897 | 4,502 | $54K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 4.2% | 3,427 | 2,496 | $52K |
| 80053 | Comprehensive metabolic panel | 3.2% | 9,726 | 8,533 | $39K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.8% | 1,664 | 1,306 | $35K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.3% | 4,657 | 4,333 | $28K |
155 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 5,357 | $17K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.3% | 1,570 | $15K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 344 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 877 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 566 | $15K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 7,061 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 357 | $10K |
| 85027 | <1% | 5,100 | $8K | |
| 84439 | <1% | 3,607 | $8K | |
| 80061 | Lipid panel | <1% | 4,990 | $8K |
| 87186 | <1% | 2,021 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 51 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,265 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,373 | $7K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 364 | $7K |
| 80074 | <1% | 565 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 665 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,238 | $6K |
| 87641 | <1% | 275 | $5K | |
| 84702 | <1% | 1,293 | $5K | |
| 83970 | <1% | 382 | $5K | |
| 81001 | <1% | 5,765 | $5K | |
| 82607 | <1% | 1,081 | $4K | |
| 83516 | <1% | 829 | $4K | |
| 87088 | <1% | 1,063 | $4K | |
| 83655 | <1% | 438 | $4K | |
| 96040 | <1% | 76 | $4K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 164 | $3K |
| 85610 | <1% | 2,232 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 410 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 23 | $3K |
| 83550 | <1% | 1,304 | $3K | |
| 86803 | <1% | 407 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 106 | $3K |
| 82784 | <1% | 415 | $3K | |
| 84481 | <1% | 1,026 | $3K | |
| 86038 | <1% | 408 | $3K | |
| 86003 | <1% | 6,149 | $2K | |
| 82746 | <1% | 896 | $2K | |
| 86696 | <1% | 372 | $2K | |
| 82570 | <1% | 2,068 | $2K | |
| 82728 | <1% | 1,310 | $2K | |
| 97161 | <1% | 26 | $2K | |
| 86235 | <1% | 244 | $2K | |
| 86140 | <1% | 1,843 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 234 | $2K |
| 87210 | <1% | 2,834 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 32 | $2K |
| 83540 | <1% | 1,323 | $2K | |
| 92523 | <1% | 45 | $2K | |
| 80055 | <1% | 323 | $2K | |
| 87077 | <1% | 570 | $2K | |
| 83735 | <1% | 936 | $2K | |
| 84153 | <1% | 307 | $2K | |
| 87070 | <1% | 709 | $2K | |
| 85652 | <1% | 2,147 | $1K | |
| 87081 | <1% | 585 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 95 | $1K |
| 97162 | <1% | 20 | $1K | |
| 82105 | <1% | 140 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 171 | $1K |
| 86592 | <1% | 1,171 | $1K | |
| 84403 | <1% | 118 | $1K | |
| 86695 | <1% | 356 | $1K | |
| 83880 | <1% | 188 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 65 | $1K |
| 82043 | <1% | 1,196 | $1K | |
| 87147 | <1% | 810 | $1K | |
| 87340 | <1% | 268 | $971.55 | |
| 86850 | <1% | 856 | $967.76 | |
| 83001 | <1% | 182 | $904.75 | |
| 99284 | Emergency room visit (serious) | <1% | 34 | $901.88 |
| 84146 | <1% | 271 | $870.47 | |
| 85007 | <1% | 1,010 | $849.46 | |
| 80076 | <1% | 327 | $789.31 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18 | $779.10 |
| 82950 | <1% | 690 | $772.51 | |
| 86901 | <1% | 862 | $766.19 | |
| 83690 | <1% | 441 | $757.26 | |
| 86162 | <1% | 106 | $714.94 | |
| 99283 | Emergency room visit (moderate) | <1% | 20 | $691.83 |
| 87338 | <1% | 69 | $682.00 | |
| 86225 | <1% | 213 | $666.46 | |
| 88141 | <1% | 458 | $651.48 | |
| 82274 | <1% | 161 | $636.34 | |
| 86255 | <1% | 232 | $610.62 | |
| 86900 | <1% | 848 | $581.75 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $570.14 |
| 86787 | <1% | 171 | $540.40 | |
| 81003 | <1% | 834 | $538.64 | |
| 87581 | <1% | 50 | $534.74 | |
| 74018 | <1% | 53 | $516.46 | |
| 87486 | <1% | 50 | $512.45 | |
| 84156 | <1% | 961 | $500.60 | |
| 84550 | <1% | 444 | $495.55 | |
| 86403 | <1% | 209 | $483.40 | |
| 86431 | <1% | 288 | $451.48 | |
| 81025 | <1% | 515 | $428.54 | |
| 84100 | <1% | 377 | $426.18 | |
| 82785 | <1% | 63 | $408.66 | |
| 81015 | <1% | 612 | $382.55 | |
| 84484 | <1% | 90 | $379.15 | |
| G0378 | Hospital observation service, per hour | <1% | 27 | $346.47 |
| 82550 | <1% | 243 | $335.80 | |
| 88341 | <1% | 20 | $304.60 | |
| 80305 | <1% | 99 | $287.89 | |
| 86800 | <1% | 64 | $278.25 | |
| 85730 | <1% | 207 | $272.79 | |
| 86376 | <1% | 118 | $241.64 | |
| 80177 | <1% | 58 | $234.26 | |
| 82565 | <1% | 153 | $227.30 | |
| 85018 | <1% | 345 | $227.08 | |
| 86141 | <1% | 27 | $197.28 | |
| 80050 | General health panel | <1% | 1,800 | $177.31 |
| 84681 | <1% | 60 | $168.78 | |
| 83002 | <1% | 118 | $168.69 | |
| 86200 | <1% | 45 | $168.65 | |
| 86762 | <1% | 92 | $168.24 | |
| 83525 | <1% | 30 | $166.91 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16 | $164.73 |
| 87205 | <1% | 147 | $164.69 | |
| 86677 | <1% | 34 | $140.50 | |
| 80306 | <1% | 53 | $128.26 | |
| 82652 | <1% | 37 | $117.16 | |
| 80164 | <1% | 42 | $112.21 | |
| 82465 | <1% | 155 | $110.27 | |
| 85014 | <1% | 214 | $109.91 | |
| 83921 | <1% | 15 | $87.92 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $77.52 |
| 88342 | <1% | 17 | $76.74 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,111 | $75.69 |
| 82150 | <1% | 66 | $74.67 | |
| 82962 | <1% | 41 | $71.75 | |
| 82951 | <1% | 12 | $67.60 | |
| 84425 | <1% | 14 | $62.40 | |
| 84630 | <1% | 13 | $44.10 | |
| 82670 | <1% | 14 | $39.66 | |
| 84165 | <1% | 12 | $35.91 | |
| 84703 | <1% | 18 | $34.81 | |
| 83615 | <1% | 41 | $34.64 | |
| 86778 | <1% | 15 | $27.45 | |
| 84480 | <1% | 12 | $23.39 | |
| 86308 | <1% | 14 | $18.72 | |
| 86777 | <1% | 15 | $18.54 | |
| 82952 | <1% | 12 | $13.07 | |
| 82947 | <1% | 12 | $13.07 | |
| 84460 | <1% | 14 | $10.15 | |
| 84590 | <1% | 15 | $9.08 | |
| 83013 | <1% | 14 | $8.38 | |
| J2704 | Injection, propofol, 10 mg | 0% | 114 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 18 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 30 | $0.00 |
| 87150 | 0% | 65 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 208 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALAS, JOSEPH (CFO)
Parent organizationMERCY HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Mercy Health System Corporation | Janesville, WI | $25.46M |
| Genesis Health System | Davenport, IA | $23.22M |
| Mercy Health System Corporation | Janesville, WI | $13.19M |
| Mercy Health System Corporation | Lake Geneva, WI | $9.39M |
| Mercy Health System Corporation | Janesville, WI | $8.15M |
| Mercy Assisted Care, INC | Janesville, WI | $4.04M |
| Genesis Medical Center, Aledo | Aledo, IL | $3.62M |
| Freeport Memorial Hospital | Freeport, IL | $1.40M |
| Mercy Health System Corporation | Janesville, WI | $1.17M |
| Mercy Assisted Care, INC | Harvard, IL | $601K |
| Mercyhealth Visiting Nurses Association, INC | Rockford, IL | $251K |
| Javon Bea Hospital | Rockford, IL | $174K |
| Genesis Health System | De Witt, IA | $136K |
| Mercy Assisted Care, INC | Janesville, WI | $136K |
| Genesis Health System | Bettendorf, IA | $32K |
| Mercy Assisted Care, INC | Janesville, WI | $12K |
| Mercy Harvard Hospital INC | Harvard, IL | $10K |
| Rockford Health Physicians | Rockford, IL | $9K |
| Mercy Health System Corporation | Janesville, WI | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.